Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches

Dear colleagues, This Special Issue, "Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches", focuses on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic a...

Full description

Saved in:
Bibliographic Details
Other Authors: Jeon, Byeong Hwa (Editor)
Format: Electronic Book Chapter
Language:English
Published: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
Subjects:
BH4
CKD
n/a
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_81021
005 20220506
003 oapen
006 m o d
007 cr|mn|---annan
008 20220506s2022 xx |||||o ||| 0|eng d
020 |a books978-3-0365-3037-6 
020 |a 9783036530369 
020 |a 9783036530376 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-0365-3037-6  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a TB  |2 bicssc 
072 7 |a TCB  |2 bicssc 
100 1 |a Jeon, Byeong Hwa  |4 edt 
700 1 |a Jeon, Byeong Hwa  |4 oth 
245 1 0 |a Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (368 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Dear colleagues, This Special Issue, "Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches", focuses on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic approaches for endothelial dysfunctions. Vascular endothelium is an active tissue and plays a crucial role in the maintenance of vascular homeostasis. Chronic exposure to risk factors, such as hypertension, high cholesterolemia, or oxidative stress, induces endothelial dysfunctions and results in a loss of endothelial integrity, smooth muscle cell proliferation, and macrophage recruitment. The pathophysiology of endothelial dysfunction (ED) is complex and multi-factorial factors are involved, such as oxidative stress or chronic inflammation. The primary prevention of cardiovascular risk factors and endothelial dysfunctions, as well as the early detection of or molecular imaging techniques for endothelial dysfunction, helps to prevent the development of cardiovascular disorders. Novel therapeutic approaches or drug delivery systems for endothelial dysfunctions have had promising beneficial effects in preclinical or clinical levels by affecting the progression of atherosclerotic changes, tumor angiogenesis, and host-immune reactions near tumor environments. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Technology: general issues  |2 bicssc 
650 7 |a Biotechnology  |2 bicssc 
653 |a endothelial cells 
653 |a oxidative stress 
653 |a inflammageing 
653 |a endothelial dysfunction 
653 |a aldehyde dehydrogenase-2 
653 |a cardiovascular disease 
653 |a neurovascular disease 
653 |a vascular inflammation 
653 |a APE1/Ref-1 
653 |a cardiovascular diseases 
653 |a subcellular localization 
653 |a serological biomarkers 
653 |a atherosclerosis 
653 |a aerobic exercise 
653 |a PCSK9 
653 |a LOX-1 
653 |a insulin resistance 
653 |a macrophage polarity 
653 |a serum γ-glutamyltransferase 
653 |a essential hypertension 
653 |a cardiovascular risk factors 
653 |a angiogenesis 
653 |a nargenicin A1 
653 |a compound 9 
653 |a VEGF 
653 |a VEGFR2 
653 |a HIF-1α 
653 |a electronegative low-density lipoprotein 
653 |a LDL(-) 
653 |a L5 LDL 
653 |a oxidized LDL 
653 |a oxLDL 
653 |a ADMA 
653 |a arginine 
653 |a arginine paradox 
653 |a BH4 
653 |a blood pressure 
653 |a COVID-19 
653 |a dietary supplements 
653 |a endothelium 
653 |a eNOS uncoupling 
653 |a heart failure 
653 |a hypertension 
653 |a L-arginine 
653 |a myocardial infarction 
653 |a NADPH 
653 |a nitric oxide 
653 |a peripheral artery disease 
653 |a ApoE knockout mouse 
653 |a atorvastatin 
653 |a VCAM-1 
653 |a galectin-3 
653 |a neutrophil/lymphocyte ratio 
653 |a electronegative LDL 
653 |a LDL(−) 
653 |a lectin-like oxLDL receptor-1 
653 |a dyslipidemia 
653 |a chronic venous insufficiency 
653 |a prolyl oligopeptidase (POP) 
653 |a inflammation 
653 |a endothelial disfunction 
653 |a lung disease 
653 |a endothelial to mesenchymal transition 
653 |a pulmonary hypertension 
653 |a pulmonary fibrosis 
653 |a metformin 
653 |a diabetes 
653 |a CV risk 
653 |a hyperglycemia 
653 |a glycated lipoproteins 
653 |a glycated LDL 
653 |a glycated HDL 
653 |a endothelial cell dysfunction 
653 |a molecular mechanisms 
653 |a epigenetic factors 
653 |a therapeutic approaches 
653 |a vasoactive factors 
653 |a EndoMT 
653 |a TGF-β 
653 |a epigenetics 
653 |a endothelial cell 
653 |a glycolysis 
653 |a metabolism 
653 |a pathological angiogenesis 
653 |a tumor microenvironment 
653 |a MRI (magnetic resonance imaging) 
653 |a high-fat diets 
653 |a plaque burden 
653 |a low-level laser therapy 
653 |a phototherapy 
653 |a vascular disease 
653 |a healing 
653 |a ischemia 
653 |a vascular calcification 
653 |a chronic kidney disease 
653 |a CKD 
653 |a uremic toxins 
653 |a hyperphosphatemia 
653 |a vascular smooth muscle cells 
653 |a VSMCs 
653 |a macrophages 
653 |a n/a 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/5363  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/81021  |7 0  |z DOAB: description of the publication